ICU Medical and GE HealthCare Vie for Medtronic’s Patient Monitoring and Respiratory Intervention Businesses

According to a recent report by Reuters,ICU Medical (NASDAQ: ICUI) and GE Healthcare (NASDAQ: GEHC) are competing for two spin-off or sale-related businesses of Medtronic.. According to sources familiar with the matter cited by the media, these companies are focusing on Medtronic's patient monitoring and respiratory intervention businesses. According to Reuters, Medtronic values these businesses between $8 billion and $9 billion.

In October, Medtronic announced its intention to separate the company's patient monitoring and respiratory interventions businesses. CEO Geoff Martha stated that by spinning off these businesses, the company aims to create value for itself and its shareholders.

At the end of last year, it was reported that GE HealthCare had expressed interest in two divisions of Medtronic's Medical Surgical portfolio. These reports also mentioned that Siemens Healthineers planned to acquire these units. Now, Reuters has reported that ICU Medical, in partnership with a private equity firm, has joined the race. According to the report, ICU Medical, in collaboration with Linden Capital Partners, submitted an asset acquisition offer. Sources stated that this bid madeICU Medical has entered the second round of the auction process.

Reuters also reported that GE HealthCare has recruited Carlyle Group and Clayton, Dubilier & Rice. The report stated that they have been individually seeking bids from rival companies.GE HealthCare has also passed the second round of bidding.

Reuters reported,Medtronic Plans to Accept Acquisition Offers for Two Units Amid SpinoffThe report said that if the upcoming offer fails to meet Medtronic's valuation, the company plans to proceed with the spin-off.

Medtronic spokesperson told Reuters that the company plans to provide more details "at the appropriate time." Medtronic declined to comment on the matter for the media regarding other related parties.

Medtronic, this medical technology giant, has been completely transformed in the past few years.

In announcing the plans to spin off these two businesses, Medtronic expects to complete the spin-offs within the next 12 to 18 months. Once a buyer is found for the company, the transaction will be subject to closing conditions. This includes final approval by the Medtronic Board of Directors, receipt of tax opinions, and other regulatory approvals.

More than a year ago, the company hinted at the possibility of a potential spin-off. At that time, analysts suggested that its diabetes and spine businesses appeared to be the most likely candidates for separation.

During Medtronic's Q2 fiscal year 2021 earnings call in November 2021, Martha stated that Medtronic currently has no specific plans to divest its diabetes business. However, he acknowledged that the company has spent "more time" reviewing its portfolio and capital allocation to "ensure we are the right owner."

In August 2022, Martha stated during the company’s first-quarter earnings call that there would be more portfolio management, including potential acquisitions and divestitures.

Medtronic announced in May 2022 its intention to form a new renal care medical device company. Medtronic and DaVita will jointly own the renal care company, each holding an equal stake. An independent management team will lead the company according to the terms of the agreement.

Earlier this month, as the number of layoffs across the industry continued to rise, the company offered early retirement. Company officials stated that this medical technology giant is "significantly cutting costs."

Regulatory filings reveal new details about the company's kidney care joint venture with DaVita, including the unveiling of a new corporate name.

In some uncertain situations, the company received some good news in Europe, as its Affera ablation system for mapping and ablating atrial arrhythmias, including AFib, obtained the CE mark.

Medtronic Updates Website, Indicating Changes in Business Operations. A Promotion Suggests the Integration of Its Surgical Robotics and Surgical Innovation Divisions.

A few days ago, Medtronic underwent a personnel change and merged its Surgical Robotics and Surgical Innovations Operating Units into one division, now called the Surgical Portfolio. Mike Marinaro has been appointed as the head of the Surgical Portfolio, and Medtronic confirmed the merger, which took effect on February 1.

The company has also partnered with Nvidia to launch the AI Access platform. This move aims to enhance the capabilities of the GI Genius intelligent endoscopy module.

Its Medtronic Global Holdings SCA subsidiary has priced a $2 billion offering of senior notes. The company aims to strengthen its ability to withstand current macroeconomic headwinds.